Literature DB >> 30046155

A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome.

Joanna Dionne1, Alexander C Ford1,1, Yuhong Yuan1, William D Chey1, Brian E Lacy1, Yuri A Saito1, Eamonn M M Quigley1, Paul Moayyedi1,1.   

Abstract

OBJECTIVE: Dietary triggers such as gluten and highly fermentable oligo-, di- and monosaccharides and polyols (FODMAP)-containing foods have been associated with worsening irritable bowel syndrome (IBS) symptoms. However, the true impact of dietary restriction on IBS symptoms has remained unclear. The aim of this study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) examining the efficacy of exclusion diets (we focused on low FODMAP and gluten-free diets (GFD)) in IBS.
METHODS: We conducted a search of the literature using the electronic databases MEDLINE (1946 to November 2017), EMBASE (1974 to November 2017), Cochrane Central Register of Controlled Trials (November 2017), and Cochrane Database of Systematic Reviews (2005 to November, 2017) for RCTs of exclusion diets in IBS. Two independent reviewers screened citations and a third reviewer resolved disagreement. Two independent reviewers performed eligibility assessment and data abstraction. For inclusion, RCTs that evaluated an exclusion diet versus an alternative or usual diet and assessed improvement in either global IBS symptoms or abdominal pain were required. Data were synthesized as relative risk of symptoms remaining using a random effects model. Quality of evidence was assessed using GRADE methodology.
RESULTS: A total of 1726 citations were identified. After full-text screening a total of nine studies were eligible for the systematic review. There were two RCTs of a GFD, involving 111 participants. Both selected patients who responded to a GFD and then randomized them to continue the diet or have the diet "spiked" with gluten. A GFD was associated with reduced global symptoms compared with a control diet (RR = 0.42; 95% CI 0.11 to 1.55; I2 = 88%), although this was not statistically significant. There were seven RCTs comparing a low FODMAP diet with various control interventions in 397 participants. A low FODMAP diet was associated with reduced global symptoms compared with control interventions (RR = 0.69; 95% CI 0.54 to 0.88; I2 = 25%). The three RCTS that compared low FODMAP diet with rigorous control diets had the least heterogeneity between studies, but also the least magnitude of effect. The overall quality of the data was "very low" according to GRADE criteria.
CONCLUSIONS: There is insufficient evidence to recommend a GFD to reduce IBS symptoms. There is very low quality evidence that a low FODMAP diet is effective in reducing symptoms in IBS patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30046155     DOI: 10.1038/s41395-018-0195-4

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  62 in total

1.  Diagnostic Utility of Carbohydrate Breath Tests for SIBO, Fructose, and Lactose Intolerance.

Authors:  Mercedes Amieva-Balmori; Enrique Coss-Adame; Nikilesh S Rao; Brisa M Dávalos-Pantoja; Satish S C Rao
Journal:  Dig Dis Sci       Date:  2019-10-15       Impact factor: 3.199

2.  Microbiome-Based Treatment Strategies for Irritable Bowel Syndrome.

Authors:  William D Chey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

3.  Highlights of the Updated Evidence-Based IBS Treatment Monograph.

Authors:  Eamonn M M Quigley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-11

4.  Update on Irritable Bowel Syndrome Guidelines.

Authors:  Brian E Lacy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-12

Review 5.  Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches.

Authors:  Gerald Holtmann; Dietmar Schrenk; Ahmed Madisch; Hans D Allescher; Gudrun Ulrich-Merzenich; Fermin Mearin; Dominique Larrey; Peter Malfertheiner
Journal:  Dig Dis       Date:  2019-11-26       Impact factor: 2.404

Review 6.  Nutraceuticals as modulators of gut microbiota: Role in therapy.

Authors:  Eamonn M M Quigley
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

7.  Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management?

Authors:  Khadijeh Abhari; Saeede Saadati; Fatemeh Hosseini-Oskouiee; Zahra Yari; Hedayat Hosseini; Golbon Sohrab; Ehsan Hejazi; Shahram Agah; Amir Sadeghi; Azita Hekmatdoost
Journal:  Eur J Nutr       Date:  2019-07-20       Impact factor: 5.614

Review 8.  All that a physician should know about FODMAPs.

Authors:  Wajiha Mehtab; Ashish Agarwal; Namrata Singh; Anita Malhotra; Govind K Makharia
Journal:  Indian J Gastroenterol       Date:  2019-12-04

9.  Changes in gut microbial metagenomic pathways associated with clinical outcomes after the elimination of malabsorbed sugars in an IBS cohort.

Authors:  A Mack; J S Bobardt; A Haß; K B Nichols; R M Schmid; C K Stein-Thoeringer
Journal:  Gut Microbes       Date:  2019-12-06

Review 10.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.